202463-68-1 Usage
Description
1-(2,4-DICHLOROPHENYL)-5-(4-IODOPHENYL)-4-METHYL-N-4-MORPHOLINYL-1H-PYRAZOLE-3-CARBOXAMIDE, also known as AM281, is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist. It is structurally an analog of the CB1 inverse agonist rimonabant and exhibits high affinity for the CB1 receptor with Kis values of 12 nM for CB1 and 4,200 nM for CB2. AM281 does not have any effect on the vanilloid TRPV1 receptor. It has been widely used in research to evaluate the potential effects of compounds at the CB1 receptor and to study the membrane localization and cycling of CB1.
Uses
Used in Pharmaceutical Research:
AM281 is used as a research tool for studying the effects of CB1 receptor modulation. It helps in understanding the role of CB1 receptors in various physiological and pathological processes, such as appetite regulation, pain perception, and neuroprotection.
Used in Drug Development:
AM281 serves as a lead compound for the development of new drugs targeting the CB1 receptor. Its high selectivity and potency make it a valuable starting point for designing more effective and safer therapeutic agents for various disorders.
Used in Neuroscience Research:
AM281 is employed in neuroscience research to investigate the role of the endocannabinoid system in the brain. It helps in elucidating the mechanisms underlying cognitive functions, emotional regulation, and the development of neurodegenerative diseases.
Used in Obesity and Metabolic Disorders Research:
AM281 is used as a potential therapeutic agent for obesity and related metabolic disorders. By blocking the CB1 receptor, it can help in reducing food intake and body weight, as well as improving insulin sensitivity and glucose metabolism.
Used in Pain Management Research:
AM281 is utilized in pain management research to explore the role of the endocannabinoid system in pain perception and modulation. Its ability to block the CB1 receptor can potentially lead to the development of novel analgesic drugs with fewer side effects compared to traditional opioids.
Used in Neuroprotection Studies:
AM281 is employed in neuroprotection studies to investigate the potential of CB1 receptor antagonism in protecting neurons from damage and degeneration. This can be particularly relevant in the context of neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis.
Biological Activity
Potent, selective CB 1 cannabinoid receptor antagonist/inverse agonist (K i values are 12 and 4200 nM for CB 1 and CB 2 receptors respectively). Increases locomotor activity following systemic administration in vivo . Analog of SR141716A (K i = 14 nM).
references
[1]. lan r, gatley j, lu q, et al. design and synthesis of the cb1 selective cannabinoid antagonist am281: a potential human spect ligand. aaps pharmsci, 1999, 1(2): e4.[2]. gatley sj, lan r, volkow nd, et al. imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid cb1 receptors in vivo. j neurochem, 1998, 70(1): 417-423.[3]. vaseghi g, rabbani m, hajhashemi v. the cb(1) receptor antagonist, am281, improves recognition loss induced by naloxone in morphine withdrawal mice. basic clin pharmacol toxicol, 2012, 111(3): 161-165.
Check Digit Verification of cas no
The CAS Registry Mumber 202463-68-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,4,6 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 202463-68:
(8*2)+(7*0)+(6*2)+(5*4)+(4*6)+(3*3)+(2*6)+(1*8)=101
101 % 10 = 1
So 202463-68-1 is a valid CAS Registry Number.
InChI:InChI=1/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)
